Peter Senter

This inventor holds 47 USPTO granted patents and 24 published patent applications, plus 8 CIPO patents and 7 EPO patents, primarily in Antibody-Drug Conjugates. Top assignees: Seattle Genetics, Inc., Seagen Inc., Bristol-Myers Company. Active years: 1989-2025.

USPTO Granted Patents = 47 (Patent Applications = 24)

% Patents Active = 97.9

CIPO Patents = 8 (Patent Applications = 12)

EPO Patents = 7 (Patent Applications = 19)

Average Co-Inventor Count = 3.3

ph-index = 24

Forward Citations = 3,183(Granted Patents)

Location History:

Seattle, WA (US) (1989 - 2022)
Bothell, WA (US) (2014 - 2024)

Company Filing History:

30 out of 132

Seattle Genetics, Inc.

Bristol-Myers Company

Bristol-Myers Squibb Compnay

Oncogen, a Limited Partnership

The Picower Institute for Medical Research

patents

where one patent can have more than one assignee

Years Active: 1989-2025

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugates

Hydrophilic Conjugates

Selective Drug Release

Protein Fucosylation

Pyrrolobenzodiazepines

Monomethylvaline Compounds

Auristatin Linkers

Pentapeptide Compounds

Recombinant Proteins

Biologically Active Compounds

Prodrugs

Cancer Treatment

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12257281 - Hydrophilic antibody-drug conjugates (2025-03-25),

2. 12036286 - Selective drug release from internalized conjugates of biologically active compounds (2024-07-16),

3. 11510959 - Hydrophilic antibody-drug conjugates (2022-11-29),

4. 11230610 - Bivalent antibodies masked by coiled coils (2022-01-25),

5. 11033561 - Methods of inhibition of protein fucosylation in vivo using fucose analogs (2021-06-15),

6. 10933112 - Hydrophilic antibody-drug conjugates (2021-03-02),

7. 10808039 - Monomethylvaline compounds capable of conjugation to ligands (2020-10-20),

8. 10561739 - Targeted pyrrolobenzodiazapine conjugates (2020-02-18),

9. 10414826 - Monomethylvaline compounds capable of conjugation to ligands (2019-09-17),

10. 10342811 - Methods of inhibition of protein fucosylation in vivo using fucose analogs (2019-07-09),

11. 9732084 - Pyrrolobenzodiazepines used to treat proliferative diseases (2017-08-15),

12. 9592240 - Targeted pyrrolobenzodiazapine conjugates (2017-03-14),

13. 9522194 - Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus (2016-12-20),

14. 9504702 - Methods of inhibition of protein fucosylation in vivo using fucose analogs (2016-11-29),

15. 9463252 - Auristatin drug linker conjugates (2016-10-11),

Title: The Innovative Journey of Peter Senter

Introduction: Peter Senter, a pioneering inventor based in Seattle, WA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Peter Senter's latest patents include a revolutionary software application for enhancing cybersecurity measures in cloud computing systems and a cutting-edge medical device designed to improve the accuracy of diagnostic procedures.

Career Highlights: With a career spanning over two decades, Peter Senter has established himself as a leading figure in the tech industry. He has worked for renowned companies such as Tech Innovations Inc. and Research Dynamics, where he spearheaded the development of state-of-the-art products that have redefined industry standards.

Collaborations: Throughout his career, Peter Senter has collaborated with top-tier engineers, designers, and researchers to bring his innovative ideas to life. His partnerships with leading universities and research institutions have resulted in the successful commercialization of several groundbreaking inventions.

Conclusion: Peter Senter's relentless pursuit of innovation and his unwavering commitment to excellence have solidified his reputation as a trailblazer in the world of technology. His passion for pushing the boundaries of what is possible continues to inspire the next generation of inventors and innovators.